---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-050889"
form_type: "8-K"
ticker: "AMRN"
cik: "0000897448"
company_name: "AMARIN CORP PLCUK"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:43:58.262659+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amarin Q1 revenue $56.5M (-34% YoY); European in-market sales +65% QoQ; GAAP loss $0.02

## Summary
- U.S. net product revenue fell 41% YoY to $48.1M on generic price erosion; gross margin narrowed to 55% from adjusted 70% a year ago.
- GAAP net loss $10.0M ($0.02/share) vs loss $16.5M ($0.04) Q1'23; non-GAAP adjusted net loss $4.7M ($0.01) vs income $7.6M ($0.02) YoY.
- European in-market sales grew ~65% Q1'24 vs Q4'23, driven by Spain (+91% patients on therapy) and UK (+28%).
- EPO issued new VAZKEPA patent extending IP protection in Europe until 2039; $50M share repurchase program approved, pending UK High Court OK in Q2.
- Cash & investments $308.2M, stable over seven quarters; on track for $40M annual cost savings from July 2023 restructuring.

## SEC filing metadata
- accession: 0000950170-24-050889
- form_type: 8-K
- ticker: AMRN
- cik: 0000897448
- company_name: AMARIN CORP PLCUK
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/897448/000095017024050889/0000950170-24-050889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/897448/000095017024050889/amrn-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-050889
- JSON: https://secwatch.observer/filing/0000950170-24-050889.json
- Plain text: https://secwatch.observer/filing/0000950170-24-050889.txt

## Key facts
- Earnings Releases
  AMARIN CORP PLCUK reported the three months ended March 31, 2024 results: revenue $56.5 million.
  - Period: the three months ended March 31, 2024
  - Revenue: $56.5 million
  - Result: reported results
  source text: Total net revenue for the three months ended March 31, 2024 was $56.5 million, compared to $86.0 million in the corresponding period of 2023, a decrease of 34%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/897448/000095017024050889/0000950170-24-050889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.